Shire plc (NASDAQ:SHPG) : Money flow in the Shire plc (NASDAQ:SHPG) stock was negative (11.89 million) on Wednesday, which shows that the investors used the strength in the stock price to reduce their holdings. The total traded value on upticks was $109.2 million, compared to $121.09 million on downticks. The total uptick to downtick ratio was 0.9, indicating the underlying weakness in the stock. Even in block trades, money flow was negative ($6.77 million), indicating selling on the strength. The transaction value during uptick in block trades was $3.6 million. Downtick transaction value in block trades amounted to $10.36 million, indicating persistent selling. The uptick to downtick ratio was 0.35. Shire plc (NASDAQ:SHPG) traded $9.66 higher at $180.66 gaining 5.65% over the previous days close.
Currently the company Insiders own 2% of Shire plc shares according to the proxy statements. Institutional Investors own 28.89% of Shire plc shares.
The company shares have dropped -29.78% from its 1 Year high price. On Jul 29, 2015, the shares registered one year high at $270.63 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $180.04 and the 200 Day Moving Average price is recorded at $176.53. Shire plc (NASDAQ:SHPG): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $177.13 and $176.05 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $181.31. The buying momentum continued till the end and the stock did not give up its gains. It closed at $180.66, notching a gain of 5.65% for the day. The total traded volume was 2,909,632 . The stock had closed at $171.00 on the previous day.
Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).